OCT 28, 2019 8:20 AM PDT

First Drug to Slow Progression of Alzheimer's Shows Promise

WRITTEN BY: Annie Lennon

An estimated 5.8 million people living in the US have Alzheimer’s disease. Currently, no cure is available and any drugs have only been able to treat its symptoms. Now however, in a surprising take, drug company Biogen has announced that their drug, Aducanumab, previously declared failure in March 2019, may be able to slow down the disease’s progression. 

Designed to target amyloid-beta plaques, a build-up of toxic proteins commonly thought to cause the neurodegeneration seen in Alzheimer’s, an earlier independent analysis of the drug found it to be ineffective in tackling the condition’s progression. It turns out however that the datasets analyzed by this study only comprised of data points until December 2018, whereas the trials continued until March 2019. 

Thus, upon analyzing the datasets made until March, in which patients received higher doses of the drug, the researchers noted significantly slower rates of cognitive and functional decline when compared to a control group. 

Al Sandrock, the head of research and development at Biogen said, “I have to pinch myself because I almost don’t believe it yet...In retrospect, the results of the futility analysis was incorrect. That’s because it was from a smaller dataset that looked at patients with less exposure to high dose aducanumab (Herper: 2019).”

Bart De Strooper, from the UK Dementia Research Institute said, “It is encouraging for the field that the tremendous work delivered to target amyloid beta appears to be validated in this trial and we should now redouble our efforts to tackle this central problem in Alzheimer’s Disease, alongside other important contributors (Hariday: 2019).”

Despite this optimism however, some are yet to be convinced. Nikolaos Robakis for example, a skeptic of the amyloid hypothesis and neuroscientists at the Icahn School of Medicine at Mount Sinai in New York City said, “Why [Biogen] came back now and said they would pursue what before they themselves they tried to discard – it seems, to me, strange.” 

This comes alongside his proposal that rather than being causes of neurodegeneration, beta-amyloid plaques are consequences of an underlying vulnerability to stress in the brain (Wadman: 2019). 

Although Biogen has yet to release comprehensive data about its two Phase 3 trials, it claims that the decision to continue Aducanumab’s development come from direct consultations with the FDA. Currently, they plan on filing an application for its approval in early 2020. 


 

Sources 

 

Hariday, Rich: New Atlas 

Herper, Matthew: Stat News 

Wadman, Meredith et al.: Science

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
MAY 08, 2020
Cannabis Sciences
Why Your Dreams Get More Intense When You Quit Cannabis
MAY 08, 2020
Why Your Dreams Get More Intense When You Quit Cannabis
Upon quitting cannabis, many notice their dreams become a lot more vivid and intense. But why?  To answer that ques ...
JUN 23, 2020
Health & Medicine
New Evidence Medical Cannabis Can Lead to Decreased Opioid Use in Chronic Pain
JUN 23, 2020
New Evidence Medical Cannabis Can Lead to Decreased Opioid Use in Chronic Pain
For people with long term ongoing pain, medical cannabis is a valid option that could pave the way to reduced use of opi ...
JUL 12, 2020
Genetics & Genomics
Some Brain Genes Have Unusually Long Introns
JUL 12, 2020
Some Brain Genes Have Unusually Long Introns
Our genome contains the genes that code for the proteins that carry out most biological functions, as well as a lot of o ...
JUL 22, 2020
Clinical & Molecular DX
Unmasking the Secrets of the Substantia Nigra to Diagnose Parkinson's
JUL 22, 2020
Unmasking the Secrets of the Substantia Nigra to Diagnose Parkinson's
Parkinson’s disease is a devastating condition whereby neurons in a specific region of the brain that controls mov ...
JUL 26, 2020
Neuroscience
How COVID-19 Causes Loss of Smell
JUL 26, 2020
How COVID-19 Causes Loss of Smell
Temporary loss of smell, known as anosmia, is one of the most common early indicators of COVID-19. Although some say it ...
AUG 05, 2020
Neuroscience
'Recycled' Brain Region Key for Ability to Read
AUG 05, 2020
'Recycled' Brain Region Key for Ability to Read
Reading and writing systems have only come to being in the last few thousand years- an insufficient timeframe to evolve ...
Loading Comments...